The latest thoracic oncology news
Lung cancer gene signatures may predict response to chemotherapy
Researchers at the Francis Crick Institute in the UK have developed a method that could…
Browsing: Lung Cancer
ESMO 2022: ADAURA trial results provide new hope for patients with early-stage non-small cell lung cancer
Newly released results from the Phase III ADAURA trial reveal that osimertinib yielded a 5.5-year…
ESMO 2022: Sotorasib demonstrates superior PFS versus docetaxel for previously treated NSCLC with KRAS G12C mutation
“In the first Phase 3 randomised clinical trial for a KRASG12C inhibitor, oral sotorasib demonstrated…
ESMO 2022: ADAURA trial results – early-stage non-small cell lung cancer
Newly released results from the Phase III ADAURA trial reveal that osimertinib yielded a 5.5-year…
ESMO 2022: Scientists discover how air pollution may trigger lung cancer in never-smokers
A new mechanism has been identified through which very small pollutant particles in the air…
Lung cancer screening increases percentage of Stage I cases detected, while reducing percentage of Stage IV cases
Implementing lung cancer screening at four diverse healthcare systems resulted in an 8.4 percent increase…
The structure of protein RAF1 revealed: a key step in the development of new drugs against lung cancer
One of the main challenges in oncology is the development of drugs against KRAS oncogenes.…
Lung cancer screening increases percentage of Stage I cases detected, while reducing percentage of Stage IV cases
Implementing lung cancer screening at four diverse healthcare systems resulted in an 8.4 percent increase…
Air pollution as a risk factor for patients with lung cancer who have never smoked
Researchers from Vancouver, British Columbia, Canada, examine the effect of duration of past exposure to…
FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer
On August 11, 2022, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki for…